Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules.


Journal

Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 31 07 2020
accepted: 13 10 2020
pubmed: 29 10 2020
medline: 22 9 2021
entrez: 28 10 2020
Statut: ppublish

Résumé

Ultrasound (US) detection of liver nodules in cirrhotic patients requires further radiological examinations and often a follow-up with repeated short-term evaluations to verify the presence of hepatocellular carcinoma (HCC). Aims of the study were to assess the rate of HCC diagnosis and to identify HCC predictors in a cohort of cirrhotics followed-up after US detection of the liver nodule(s). One-hundred-eighty-eight consecutive cirrhotic patients (124 males, mean age 64.2 years) with liver nodule(s) detected by US were enrolled. All patients underwent second-level imaging [computed tomography (TC) or magnetic resonance (MR)], and those without a definite diagnosis of HCC were followed-up with TC and/or RM repeated every 3-6 months up to 18 months if HCC was not diagnosed. After 18 months, non-HCC patients came back to routine US surveillance. HCC was diagnosed in 73/188 cases (38.8%). In 66/73 patients (90.4%) HCC was identified at first radiological evaluation after US, while in the remaining seven subjects it was diagnosed at the subsequent imaging examination. Age (p = 0.001) and nodule dimension (p = 0.0001) were independent predictors of HCC at multivariate analysis. Fourty-nine/188 patients were lost at follow up after 18 months. Twenty/139 remaining patients developed HCC and 3/139 cholangiocarcinoma; 77 died between 3 and 110 months from the beginning of the study (61 for end-stage liver disease, 8 for extrahepatic causes, eight for unknown causes). Patients who developed liver cancer earlier during the follow up had the shortest overall survival. US-detected liver nodules are not neoplastic in more than half of cirrhotic patients. A definite diagnosis may be obtained at the time of the first radiologic evaluation after US in the vast majority of the cases. Patients in whom nodules are found not to be tumoral may return to the US surveillance program routinely applied to all cirrhotics.

Identifiants

pubmed: 33111165
doi: 10.1007/s11739-020-02541-7
pii: 10.1007/s11739-020-02541-7
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

949-955

Références

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255. https://doi.org/10.1016/S0140-6736(11)61347-0
doi: 10.1016/S0140-6736(11)61347-0 pubmed: 22353262
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127. https://doi.org/10.1056/NEJMra1001683
doi: 10.1056/NEJMra1001683 pubmed: 21992124
Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30:3–16. https://doi.org/10.1055/s-0030-1247128
doi: 10.1055/s-0030-1247128 pubmed: 20175029
Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 37:838–851. https://doi.org/10.1016/S0140-6736(08)60383-9
doi: 10.1016/S0140-6736(08)60383-9
Kokudo N, Takemura N, Hasegawa K et al (2019) Evidence-based clinical practice guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 49:1109–1113. https://doi.org/10.1111/hepr.13411
doi: 10.1111/hepr.13411 pubmed: 31336394
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750. https://doi.org/10.1002/hep.29913
doi: 10.1002/hep.29913 pubmed: 29624699
Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422. https://doi.org/10.1007/s00432-004-0552-0
doi: 10.1007/s00432-004-0552-0 pubmed: 15042359
McMahon BJ, Bulkow L, Harpster A et al (2000) Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32:842–846. https://doi.org/10.1053/jhep.2000.17914
doi: 10.1053/jhep.2000.17914 pubmed: 11003632
Wong LL, Limm WM, Severino R, Wong LM (2000) Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6:320–325. https://doi.org/10.1053/lv.2000.4875
doi: 10.1053/lv.2000.4875 pubmed: 10827233
Oka H, Kurioka N, Kim K et al (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687
doi: 10.1002/hep.1840120411
Filomia R, Maimone S, Caccamo G et al (2016) Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. Medicine (Baltimore) 95:e4836. https://doi.org/10.1097/MD.0000000000004836
doi: 10.1097/MD.0000000000004836
Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R et al (2016) Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol 26:144–155. https://doi.org/10.18176/jiaci.0058
doi: 10.18176/jiaci.0058 pubmed: 27326981
Guevara M, Fernandez-Esparrach G, Alessandria C et al (2004) Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40:646–651. https://doi.org/10.1002/hep.20373
doi: 10.1002/hep.20373 pubmed: 15349903
Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39:930–936. https://doi.org/10.1053/ajkd.2002.32766
doi: 10.1053/ajkd.2002.32766 pubmed: 11979336
Najjar M, Hamad A, Salameh M, Agarwal A, Feinfeld DA (2002) The risk of radiocontrast nephropathy in patients with cirrhosis. Ren Fail 24:11–18
doi: 10.1081/JDI-120002656
Morcos SK, Thomsen HS, Webb JA (1999) Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 9:1602–1613
doi: 10.1007/s003300050894
Brix G, Lechel U, Nekolla E, Griebel J, Becker C (2015) Radiation protection issues in dynamic contrast-enhanced (perfusion) computed tomography. Eur J Radiol 84:2347–2358. https://doi.org/10.1016/j.ejrad.2014.11.011
doi: 10.1016/j.ejrad.2014.11.011 pubmed: 25480677
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases (2009) Liver biopsy. Hepatology 49:1017–1044. https://doi.org/10.1002/hep.22742
doi: 10.1002/hep.22742
Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596. https://doi.org/10.1136/gut.2008.149062
doi: 10.1136/gut.2008.149062 pubmed: 18669577
Huang JF, Hsieh MY, Dai CY et al (2007) The incidence and risks of liver biopsy in non-cirrhotic patients: an evaluation of 3806 biopsies. Gut 56:736–737. https://doi.org/10.1136/gut.2006.115410
doi: 10.1136/gut.2006.115410 pubmed: 17440193 pmcid: 1942123
Cadranel JF, Rufat P, Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32:477–481. https://doi.org/10.1053/jhep.2000.16602
doi: 10.1053/jhep.2000.16602 pubmed: 10960438
Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36:437–441
doi: 10.1136/gut.36.3.437
Sharma P, McDonald GB, Banaji M (1982) The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 4:451–453
doi: 10.1097/00004836-198210000-00011

Auteurs

Maria Stella Franzè (MS)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.

Antonio Bottari (A)

Division of Radiology, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.

Simona Caloggero (S)

Division of Radiology, Department of Radiology and Radiotherapy, University Hospital of Messina, Messina, Italy.

Alessia Pitrone (A)

Division of Radiology, Department of Radiology and Radiotherapy, University Hospital of Messina, Messina, Italy.

Adalberto Barbera (A)

Division of Oncologic Surgery, Department of Human Pathology, University of Messina, Messina, Italy.

Tindaro Lembo (T)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.
Present address: Unit of Internal Medicine, Institute of Social Security, San Marino, Republic of San Marino.

Gaia Caccamo (G)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.

Irene Cacciola (I)

Division of Medicine and Hepatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Sergio Maimone (S)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.

Angela Alibrandi (A)

Division of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina, Italy.

Concetta Pitrone (C)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.

Giovanni Squadrito (G)

Division of Internal Medicine, Department of Medical Sciences, University Hospital of Messina, Messina, Italy.

Giovanni Raimondo (G)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy.
Division of Medicine and Hepatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Carlo Saitta (C)

Division of Medicine and Hepatology, Department of Medical Sciences, University Hospital of Messina, Via Consolare Valeria, 1 - 98124, Messina, Italy. csaitta@unime.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH